Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.65 HKD | +0.42% |
|
-10.54% | -23.17% |
06-04 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
06-03 | Summit Therapeutics Inc. Expands License Territories for Ivonescimab | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.17% | 3.95B | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- 9926 Stock
- News Akeso, Inc.
- Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%